Ranking · Summer 2020 · Healthcare · Drug Discovery and Delivery

Nabla Bio

We use AI to design antibodies for intractable diseases

6.7%

odds of being acquired in the next two years

1.0× the average (6.8%)

#2107 of 4,339 active YC companies · top 50%

Team of 8 · Boston, MA, USA

Raises the odds

↑ team of 6–10

↑ based in United States of America

↑ based in America / Canada

↑ changed its name (pivot)

Lowers the odds

↓ industry: Healthcare

↓ “design” in its one-liner

↓ sector: Drug Discovery and Delivery

From the model: how this company's profile compares with companies that were and weren't acquired since 2024. How it works.

Signals brief

ExitOdds reads Nabla Bio's website and YC profile; Contextrie keeps the passages that bear on an acquisition, and every signal quotes its source.

3 free briefs left today

nabla.bio YC profile

Statistical estimate from public directory data as of 2026-10-07; it can't see revenue, funding or talks. Not investment advice. ExitOdds is independent and not affiliated with Y Combinator.

Built with open source on GitHub